Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 6Phase EARLY_PHASE1 2Phase NA 1Phase 4 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Pituitary Neoplasms 15Neuroendocrine Tumors 15Multiple Endocrine Neoplasia Type 1 9Inflammation 4Acromegaly 4Sexual Dysfunction, Physiological 3Pheochromocytoma 3Obesity 3Neoplasms 3Gastro-enteropancreatic neuroendocrine tumor 3Thyroid Cancer, Papillary 2Prostatic Neoplasms 2Pituitary Diseases 2Paraganglioma 2Carcinoid Tumor 2Adrenal Gland Neoplasms 2Zollinger-Ellison Syndrome 1Vitamin D Deficiency 1Serotonin Syndrome 1Pituitary ACTH Hypersecretion 1Pancreatic Neuroendocrine Tumors 1Pancreatic Neoplasms 1Pain, Postoperative 1Pain 1Neuroendocrine Tumour With Carcinoid Symptoms 1Multiple Endocrine Neoplasia 1Meningioma 1Melanoma 1Medulloblastoma 1Lung Neoplasms 1

Interventions

pasireotide 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Pituitary ACTH Hypersecretion × Endocrine × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡